Contents -- Contributors -- SECTION I: BIOLOGICAL BASES OF PEDIATRIC PSYCHOPHARMACOLOGY -- I-A: DEVELOPMENTAL PRINCIPLES OF NEUROBIOLOGY AND PSYCHOPHARMACOLOGY -- 1. Overview of Brain Development -- 2. Synaptic Function and Biochemical Neuroanatomy -- 3. Mechanisms of Signal Transduction and Adaptation to Psychotropic Drug Action -- 4. Pharmacokinetics I: Developmental Principles -- 5. Pharmacokinetics II: Cytochrome P450-Mediated Drug Interactions -- I-B: GENETIC PRINCIPLES -- 6. Molecular Genetics -- 7. Pharmacogenetics -- I-C: DEVELOPMENTAL PSYCHOPATHOLOGY -- 8. Neurobiology of Attention Regulation and its Disorders -- 9. Neurobiology of Early-Life Stress and its Disorders -- 10. Neurobiology of Early-Onset Mood Disorders -- 11. Neurobiology of Early-Onset Anxiety Disorders -- 12. Neurobiology of Obsessive-Compulsive Disorder -- 13. Neurobiology of Tic Disorders, Including Tourette's Syndrome -- 14. Neurobiology of Immune-Mediated Neuropsychiatric Disorders -- 15. Neurobiology of Childhood Schizophrenia and Related Disorders -- 16. Neurobiology of Affiliation: Implications for Autism Spectrum Disorders -- 17. Neurobiology of Aggression -- 18. Neurobiology of Eating Disorders -- 19. Neurobiology of Substance Abuse and Dependence Disorders -- SECTION II: SOMATIC INTERVENTIONS -- II-A: PSYCHOTROPIC AGENTS -- 20. Stimulants -- 21. Adrenergic Agonists: Clonidine and Guanfacine -- 22. Antidepressants I: Selective Serotonin Reuptake Inhibitors -- 23. Antidepressants II: Tricyclic Agents -- 24. Antidepressants III: Other Agents -- 25. Mood Stabilizers: Lithium and Anticonvulsants -- 26. Antipsychotic Agents: Traditional and Atypical -- 27. Anxiolytics: Benzodiazepines, Buspirone, and Others -- 28. Miscellaneous Compounds: Beta-Blockers and Opiate Antagonists -- II-B: OTHER SOMATIC INTERVENTIONS.

29. Complementary and Alternative Medicine in Pediatric Psychopharmacology -- 30. Electroconvulsive Therapy and Transcranial Magnetic Stimulation -- SECTION III: ASSESSMENT AND TREATMENT -- III-A: GENERAL PRINCIPLES -- 31. Clinical Assessment of Children and Adolescents Treated Pharmacologically -- 32. Clinical Instruments and Scales in Pediatric Psychopharmacology -- 33. Thinking About Prescribing: The Psychology of Psychopharmacology -- 34. Combining Pharmacotherapy and Psychotherapy: An Evidence-Based Approach -- III-B: SPECIFIC DISORDERS AND SYNDROMES -- 35. Attention-Deficit Hyperactivity Disorder -- 36. Depressive Disorders -- 37. Bipolar Disorder -- 38. Anxiety Disorders -- 39. Obsessive-Compulsive Disorder -- 40. Tourette's Syndrome and Other Tic Disorders -- 41. Early-Onset Schizophrenia -- 42. Autistic and Other Pervasive Developmental Disorders -- 43. Post-traumatic Stress Disorder -- 44. Eating Disorders -- III-C: SPECIAL CLINICAL POPULATIONS -- 45. Substance-Abusing Youths -- 46. Individuals with Mental Retardation -- 47. The Medically Ill Child or Adolescent -- 48. Psychopharmacology During Pregnancy: Infant Considerations -- 49. Psychopharmacological Treatment of Preschoolers -- III-D: OTHER AREAS OF CLINICAL CONCERN -- 50. Agitation and Aggression -- 51. Elimination Disorders: Enuresis and Encopresis -- SECTION IV: EPIDEMIOLOGICAL, RESEARCH, AND METHODOLOGICAL CONSIDERATIONS -- 52. Pediatric Psychopharmacoepidemiology: Who Is Prescribing? And For Whom, How, and Why? -- 53. Clinical Trials Methodology and Design Issues -- 54. Regulatory Issues -- 55. Ethical Issues in Research -- 56. International Perspectives -- Appendix: Pediatric Psychopharmacology at a Glance -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- J -- K -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U -- V -- W -- X -- Y -- Z.